Research Article
Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients
Table 1
General characteristics of the enrolled patients ().
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NAFLD: nonalcoholic fatty liver disease; BMI: body mass index; WHtR: waist-to-height ratio; AST: aspartate aminotransferase; ALT: alanine aminotransferase; γGT: gamma glutamyl transpeptidase; FPG: fasting plasma glucose; HOMA-IR: homeostatic model assessment for insulin resistance; TCH: total cholesterol; TG: triglycerides; LDL: low-density lipoprotein; CRP: C reactive protein; TNF-α: tumor necrosis factor-alpha; EGFR: epidermal growth factor receptor; CD-44: cluster of differentiation 44; IL-18: interleukin-18; IGF-II: insulin growth factor-II; IL-22: interleukin-22; TGF-β: transforming growth factor-beta; MMP-2: metalloproteinase-2; HMGB-1: high mobility group box-1; TBARS: thiobarbituric acid reactive substances. |